# Index

absolute risk reduction (ARR) see risk difference

abstracts 55, 352–5
  adverse effects 441–2
  non-randomized studies 406
Overviews of reviews 615–16
searching 98, 110, 143, 145, 406, 441–2
selecting studies 153
accumulation of changes 38
acknowledgements 68, 624
ACR see assumed control risks
Additional tables 72, 234, 350–1, 468, 539
adherence 160, 369
adverse effects 433–48
  data collection 161–2
  definitions 434
  drop-outs 438
  eligibility criteria 434–8
  narrow/broad focus 437–8
  non-randomized studies 397, 400, 427, 438, 443–5
review questions 90
  risk of bias/quality 442–5
searching 439–42
separate reviews 436–7
sources of information 439–40
strategies for addressing 434–7
Summary of findings tables 348–9
types of studies 438, 442–5
Adverse Effects Methods Group (AEMG) 446
advisory groups 19–20
AEMG see Adverse Effects Methods Group
aetiological research questions 399
agreement measures 155–6, 169
allied health-specific databases 103–4
allocation concealment 193, 211, 214–17
results sections 65

Risk of bias tool 196, 198–9, 203–4
amendments 33, 34–7
analysing data see meta-analysis
analysis of covariance (ANCOVA) 270
analysis plans 58, 60–3, 244–6, 564, 565
  prospective meta-analyses 564, 565
ANCOVA see analysis of covariance
appendices 78
search strategies 144, 146
applicability
discussion sections 66
interpreting results 367–9
Overviews of reviews 622–3
public health and health promotion 601–3
Applicability and Recommendations Methods Group (ARMG) 383
ARR (absolute risk reduction) see risk difference
as-treated analyses 225
assessing a review as up to date 40, 43–4, 54, 625–6
assumed control risks (ACR) 347, 349, 374, 376–7
attrition bias 194–6, 200, 219
authors’ conclusions see conclusions
authorship 36, 38, 39, 52–3
available case analysis 489, 490, 492
background sections 56–7, 617–18
baseline imbalance 231–2
baseline risk see control group risk
Bayesian methods 210, 518–19
before-and-after studies 393, 596–7
bias see publication bias; reporting bias; risk of bias
Bias Methods Group (BMG) 324
bibliographic databases 98–107
INDEX

binary outcome data see dichotomous outcome data
biologic variation 368
biology-specific databases 103
blinding 193–4, 217–9
results sections 65
review authors 168, 192, 382
Risk of bias tool 195–196, 199, 203–4, 217–19
blocked randomization 194, 212, 232
BMG see Bias Methods Group
Boolean operators 132–3, 141
broad questions 91–3
Campbell and Cochrane Economics Methods Group (CCEMG) 454, 463, 468, 475, 543
Campbell Collaboration 147
Campbell Coordinating Groups 584
Campbell Equity Methods Group 597–8
carry-over effects 499–503
case reports 438, 444–5
case series 393, 438
case-control studies 393, 399, 415–16, 438, 443–4
CBA see cost-benefit analysis
CBT see cognitive behavioural therapy
CCEMG see Campbell and Cochrane Economics Methods Group
CCTs see controlled clinical trials
CDSR see Cochrane Database of Systematic Reviews
CEA see cost-effectiveness analysis
CENTRAL see Cochrane Central Register of Controlled Trials
central randomization 216
Centre for Reviews and Dissemination (CRD) 111, 460–2, 463
CGR see control group risk
deresults sections 65
change scores 172, 269–70
standard deviations 485–8
changing review questions 93
Characteristics of studies tables 63–4, 70–2
economics evidence 468
excluded studies 64, 71, 154
included studies 63–4, 70, 336–7, 468
ongoing studies 64, 72
Overviews of reviews 620, 625–6
studies awaiting classification 64, 71
checklists 191
chi-squared tests 277–8, 281, 284, 338–9
CINAHL database 103, 579
citation
bias 298, 306
indexes 105
versions 33–6, 37–9, 55
citing
protocols 58
reviews 25–6
clinical event pathways 455–6
clinical trials see randomized trials
cluster-randomized trials 260, 493–8
effective sample sizes 495–7
inflating standard errors 497
meta-analysis 495–6, 497
methods of analysis 495
public health and health promotion 594, 595, 599
risk of bias 494–5
sensitivity analyses 291
CMR see Cochrane Methodology Register
Cochrane, Archie 4, 450
Cochrane Central Register of Controlled Trials (CENTRAL) 5, 98–100, 108, 118–29, 133, 139–42, 406
Cochrane Collaboration 3–6
maintenance of Cochrane reviews 32
preparation of Cochrane reviews 11, 18, 24–8
principles 4, 8
publication of Cochrane reviews 5–6
structure 4–5
Cochrane Database of Systematic Reviews (CDSR) 5–6
citation 33–6
dates 40, 54–5
Overviews of reviews 608
prospective meta-analyses 566
protocols 12–13, 17
searching see Cochrane Library
withdrawn reviews 46
Cochrane Health Equity Field 597–8
Cochrane Library 5
Cochrane Review Groups 22–4
economics evidence 460–1
feedback 48
Overviews of reviews 608
searching 99–100, 119, 121, 124–6, 133–4
Cochrane Methodology Register (CMR) 5
INDEX

Cochrane Review Groups (CRGs) 4–5, 7
- economics evidence 453–4
- guidance and support 17, 20–4, 27, 59, 68, 91
- maintenance of Cochrane reviews 32, 35, 37–8, 41, 45–6, 48
- non-randomized studies 398, 399–400, 403, 406–7

Overviews of reviews 607–8, 613
- plain language summaries 355–6
- prospective meta-analyses 566
- public health and health promotion 595
- qualitative research 576, 583–4
- searching 59–60, 96–8, 102, 108, 118–19, 123–5, 130, 144
- statisticians 292

Cochrane reviews
- Diagnostic test accuracy 7, 20
- Intervention 6–7, 12–16
- Methodology 20
- Overviews of reviews 20, 607–31
- coding schemes 167
- cognitive behavioural therapy (CBT) 536
- cohort studies 393, 399, 415, 438, 443–4
- collaborations
  - individual patient data 549, 550–1
  - prospective meta-analyses 562–3
- see also Cochrane Collaboration
- combining studies see meta-analysis
- combining subgroups/intervention groups 177
- comments and criticisms see feedback
- commercial interests 26–8, 303–4, 624
- community healthcare-specific databases 104
- comparisons 74–5, 86–7, 245, 247–8
- completeness of evidence 66
- concealment of allocation see allocation concealment
- conclusions 67, 380–2
- abstract 353, 355
- changed 34, 37–8
- economics evidence 474
- Overviews of reviews 616, 623–4
- qualitative research 578
- conditional outcomes 492–3
- conference abstracts/proceedings 110–11
- confidence intervals 369–71
  - continuous outcome data 172–5, 370
  - data extraction 173–5, 181–2
  - dichotomous outcome data 171, 370
  - forest plots 338
  - rare events 522
  - Summary of findings tables 349–50
- confidentiality 550–1, 563
- conflicts of interest see declarations of interest
- confounding
  - GRADE/quality of evidence 362, 366
  - heterogeneity 287
  - indirect comparisons 514
  - non-randomized studies 395, 397, 412, 416–17, 420–2, 425–6
  - public health and health promotion 594
- consensus 169
- consistency see heterogeneity
- consumer involvement 18–19
- contact persons 53–4
- contents of Cochrane reviews 12–16, 51–79
  - abstracts 55
  - appendices 78
  - data and analyses 74–5
  - feedback 77
  - figures 76–7
  - plain language summaries 55
  - protocol information 52–5
  - review information 52–5
  - studies and references 72–4
  - tables 70–2
  - text 55–70
  - titles 52–3
- context 368–9, 599–600
- continuous outcome data 250, 255–7
  - confidence intervals 172–5, 370
  - counts 179
  - data extraction 171–7, 179
  - forest plots 338–9
  - funnel plots 317–18
  - individual patient data 554, 555
  - intention to treat 491–2
  - interpreting results 377–9
  - meta-analysis 268–72, 290
  - non-randomized studies 421
- Overviews of reviews 629
- results sections 338–9, 349, 370, 377–9
- risk of bias 200, 223–4, 227
- Summary of findings tables 349
- see also patient-reported outcomes
- contour-enhanced funnel plots 313–15
- contributions of authors 68–9
- control group risk (CGR)
  - effect measures 251–3
  - interpreting results 346–7, 349, 374, 377
- meta-regression 288–9
- see also assumed control risk
INDEX

636

controlled
before-and-after studies 393
vocabulary 130–1, 440, 538–9
controlled clinical trial (CCT) 119–23, 126
copyright 97–8
correlation coefficients 486–8, 496–8, 505–7
correspondence with investigators 163, 166, 193
cost data 470–1
cost-benefit analysis (CBA) 451, 452, 457
cost-effectiveness analysis (CEA) 451, 452, 457, 472–3
cost-utility analysis (CUA) 451, 452
count data 250, 258
data extraction 178–9
meta-analysis 273–4, 521
zero-cell 521
covariates 284–5, 422
Cox model 180, 275, 421
CRD see Centre for Reviews and Dissemination
CRGs see Cochrane Review Groups
critical appraisal
qualitative research 580–1, 590–1
see also quality, risk of bias
cross-over trials 261, 498–508
eligibility criteria 499
meta-analysis 502–7
methods of analysis 501–2
risk of bias 499–501
sensitivity analyses 291
unit of analysis errors 261, 502
cross-sectional studies 393, 415
CUA see cost-utility analysis
cultural factors 360, 368–9
DARE see Database of Abstracts of Reviews of Effects
data
collection 156–67
abstracts 353, 354
economics evidence 462–3, 466
forms 164–7
individual patient data 551–3
interventions 157, 159–60
methods of studies 157, 158
methods sections 60–3
non-randomized studies 407–11
outcomes 157, 161–2
Overviews of reviews 614, 619
participants 157–9
prospective meta-analyses 564, 566–7
results 157, 162
risk of bias 192–3
sources of data 157, 163–4
sustainability 600
entry 170–1, 175, 180–2
extraction 167–82
consensus 169
continuous outcome data 171–7, 179
conversion to desired format 170–82
counts 178–9
dichotomous outcome data 170–1, 179
estimates of effects 180–2
multiple reports 168–9
ordinal outcome data 178
Overviews of reviews 619–20
results 170–82
time-to-event data 179–80
management 182–3
individual patient data 551–3
Overviews of reviews 619–20
prospective meta-analyses 564, 566, 567–8
synthesis see meta-analysis
time to event see time-to-event data
types 249–59
see also continuous outcome data; count data;
dichotomous outcome data; ordinal outcome data; rate data; time-to-event data
Data and analysis section 74–5, 337–41, 351
Database of Abstracts of Reviews of Effects (DARE) 5, 111
dates 39–41, 42, 54–5, 134
declarations of interest 26–8, 69, 624
derivative products 27
DerSimonian and Laird method see random-effects methods
descriptions of condition/intervention 57
design-specific risk of bias 230
detection bias 195
diagnostic test accuracy 7
dichotomous outcome data 249–55
confidence intervals 171, 370
counts 179
data extraction 170–1, 179
forest plots 338
funnel plots 312, 318–19
individual patient data 554, 555
intention to treat 490–1
interpreting results 372–7
meta-analysis 265–8, 271–2, 520–3
non-randomized studies 421
patient-reported outcomes 541
INDEX 637

risk of bias 200, 208, 223, 227
summary of findings tables 346–7, 349
difference measures 181–2, 254, 255–7, 372–7
difference in means 255–6, 377–8
cross-over trials 503–5
funnel plots 317–19
meta-analysis 268–72
differential diagnostic activity 232
directly observed therapy (DOT) 576–9
directness see indirect evidence
discussion sections 66–7, 622–3
dissertations databases 106
dose-response analyses 289, 362, 367
DOT see directly observed therapy
double-blinding see blinding
Downs and Black instrument 418
drop-outs see incomplete outcome data
Drummond checklist 465–6
duplicated data see multiple reports
early stopping 231
economics evidence 449–79
clinical event pathways 455–6
data analysis 466–72
data collection 462–3, 466
eligibility criteria 457–9, 462, 465–6
evaluation types 450–3
meta-analysis 470–1
model development 471–2
outcomes 456–7
reporting bias 472–3
review questions 90, 454–6
risk of bias/quality 463–7, 470
role and relevance 449–54
searching 459–62
strategies for addressing 457–9
types of evidence 457–9, 463–7, 450–3
editorial procedures 21–2, 46
education-specific databases 104
effect
estimates 180–2, 263–5
measures 61, 250–9, 279–80
modification 282
size 256–7
Effective Practice and Organisation of Care (EPOC) Group 596
effectiveness 399, 597–8
Effectiveness and Efficiency (Cochrane) 450
effects of interventions section 65–6
Electronic Information for Libraries (eIFL) 99, 109
eligibility criteria 84–94, 151–4
abstracts 353–4
adverse effects 435–8
Cochrane Review Groups 22
cross-over trials 499
data collection 157, 165–6
economics evidence 457–9, 462, 465–6
excluded studies 154
measures of agreement 155–6
methods sections 58–9
multiple reports 152
non-randomized studies 396–403,
407, 425
Overviews of reviews 609–12, 614, 618–19,
625
prospective meta-analyses 559–61, 564–5
qualitative research 577
references 73
searching 128
selection process 151–6
sensitivity analyses 290
studies versus reports 152
unpublished studies 308–9
updates and amendments 44
EMBASE 98–102, 118
adverse effects 440–1
CENTRAL 121
economics evidence 460
non-randomized studies 404
qualitative research 579
reporting bias 305
searching for reviews 111–12
searching for studies 125–31, 139
EPICOT acronym 381
EPOC see Effective Practice and Organisation of Care
EPPI see Evidence for Policy and Practice Information
errata 37, 38, 134–5
estimates of effect see effect estimates
ethics 234, 597–8
Evers checklist 465, 467
Evidence for Policy and Practice Information (EPPI) Centre 580, 582, 591
excluded studies 154
Overviews of reviews 625
reporting bias 308–9
results sections 64
sensitivity analyses 280, 290
table 71, 73
see also eligibility criteria
INDEX

exclusions 194, 196, 200, 219–21
see also intention to treat
explanatory variables 284–5
external funding 77, 303–4
factorial trials 508, 512–13
fail-safe N 321–2
false negatives 283
false positives 283–4, 318
feedback 48, 77
figures 76–7, 341–2
Overviews of reviews 630
risk of bias 202–4, 207
see also forest plots; funnel plots
file drawer problem 299
first published dates 54
fixed-effect method 264, 279
confidence intervals 279, 370
forest plots 338–9
reporting bias 319–21
RevMan 265, 268–9, 275
sensitivity analyses 291, 319–21
forest plots 76, 337–40
figures 341–2
heterogeneity 277, 284
non-randomized studies 423–4
results sections 351
risk of bias 207
see also forest top plots
forest top plots 342, 630
format of Cochrane reviews 12–16
see also contents of Cochrane reviews
fraudulent studies 134–5
free-text terms 130–1, 441–2, 539
full economic evaluations 451–2
full-text electronic journals 108–9
full-text reports 153
functional status 534
funding
preparation of Cochrane reviews 24
risk of bias 233
funnel plots 310–19
figures 76, 341
non-randomized studies 404
tests for asymmetry 314–19
GDP see gross domestic product
generic inverse-variance outcome data 265
cluster-randomized trials 495, 497
combining dichotomous and continuous outcome data 272
cross-over trials 504, 507
counts and rates 274
data extraction 180–1
forest plots 339
non-randomized studies 423
ordinal outcome data 272
RevMan 265, 275, 339–40
see also inverse-variance meta-analysis
GRADE 350, 361–7, 383
non-randomized studies 427
Overviews of reviews 620, 622, 623, 628–9
GRADEprofiler software 344–6
graphs see figures
grey literature
databases 106–7, 118, 145
reporting bias 308–9
gross domestic product (GDP) 468
group-allocated studies see cluster-allocated studies
handsearching 107–8, 120
harms see adverse effects
hazard ratio 259, 275, 423
headings 56
health equity 597–8
Health InterNetwork Access to Research Initiative (HINARI) 99, 109
health promotion-specific databases 103
see also public health and health promotion
health status 534–5
Health Technology Assessment Database (HTA) 111
health-related quality of life (HRQOL) 533–6, 538, 540, 542–3
health-specific databases 102–5
healthcare librarians 118–19
heterogeneity 276–89
addressing 278–80
analysis plans 249, 286, 288
baseline risk 288–9
definitions 276–7
dichotomous outcome data 267
dose-response analyses 289
economics evidence 469
forest plots 338–9
GRADE/quality of evidence 362, 365
I-squared 278, 282
identification and measurement 277–8
interaction and effect modification 282
meta-regression 284–8
methods sections 62
INDEX

multi-arm studies 511–12
non-randomized studies 412, 419, 423–4, 426
Overviews of reviews 629
rare events 523
reporting bias 313, 318
subgroup analyses 282–8
tau-squared 281, 318, 338–9
testing 277–8, 281
see also random-effects method
hierarchical models 519–20
highly sensitive search strategies 135–9, 141–2
HINARI see Health InterNetwork Access to Research Initiative
historically controlled studies 393
History tables 46–8, 55
homogeneity see heterogeneity
HRQOL see health-related quality of life
HTA see Health Technology Assessment Database
I-squared 278, 281
ICC see intracluster correlation coefficients
ICER see incremental cost-effectiveness ratio
ICMJE see International Committee of Medical Journal Editors
identifiers 73, 143, 157, 166
implications for practice/research 67, 380–2
imputations
change from baseline 270, 485–8
cluster-randomized trials 496
cross-over trials 503, 505–7
intention to treat 225–6, 484, 490–2
standard deviations 485–8
IMRG see Information Retrieval Methods Group
IMS see Information Management System
incomplete outcome data 194, 219–26
attrition/drop-out 194, 220, 438
exclusions 194, 196, 200, 219–21
results sections 65
Risk of bias tool 195–196, 200, 203–4, 219–26
see also intention to treat; missing data; selective outcome reporting
incremental cost-effectiveness ratio (ICER) 457
index terms see controlled vocabulary
indirect comparisons 363, 513–15, 621, 630
indirect evidence 362, 363–5
individual patient data (IPD) 164, 547–58
benefits and limitations 549, 553, 555–6
collaborations 549, 550–1
confidentiality 550–1
data collection 164, 551–3
meta-analysis 520, 553–5
prospective meta-analyses 560–3
individual patient data meta-analysis methods group (IPD MA MG) 549–50, 555, 557
inequalities 597–8
Information Management System (IMS) 20–1
Information Retrieval Methods Group (IRMG) 147, 407
integrity of interventions 89, 159–60, 601
intention to treat (ITT) 220–1, 488–93
interaction 282
interim analyses 231, 567–8
International Committee of Medical Journal Editors (ICMJE) 309–10
interpreting results 359–87
continuous outcome data 377–9
dichotomous outcome data 372–7
economics evidence 474
meta-regression 287–8
non-randomized studies 424–8
patient-reported outcomes 541–3
subgroup analyses 287–8
interrupted-time-series studies 176
intracluster correlation coefficient (ICC) 496–8
inverse-variance meta-analysis 264–5
continuous outcome data 268
dichotomous outcome data 265–7
fixed-effect method 264
random-effects method 266, 272–3, 275
rare events 521, 523
RevMan 275
see also generic inverse-variance outcome data
IPD see individual patient data
IPD MA MG see individual patient data meta-analysis methods group
IRMG see Information Retrieval Methods Group
ITT see intention to treat
Joanna Briggs Institute (JBI) 580, 582, 591
kappa statistics 155–6, 169
L’Abbé plots 342
language
bias 97, 298, 306–7
restrictions 134
last edit date 41
last observation carried forward (LOCF) 225–6
licensing 97–8
location bias 298, 305–6
LOCF see last observation carried forward
log scales 176, 182, 259–60, 263, 271, 312
log-rank statistics 180, 275
main outcomes 88–9, 343
main text sections see text sections
maintenance of Cochrane reviews 31–49
amendments 33, 34–7
conclusions changed 34, 37–8
dates 39–41
definitions 32–9
editorial procedures 46
feedback 48
frequency 32
History tables 46–8
major changes 34, 35
methods 45
protocols 11–12, 33–6
review questions 42–4, 93
splitting reviews 44–5
updates 33–4, 36, 37, 41–6
What’s new events 41, 46–7
withdrawn reviews 17, 33, 46, 70
major changes to protocols 34, 35
Mantel-Haenszel methods 266, 282
forest plots 338
non-randomized studies 421
rare events 521, 523
RevMan 275, 339
test for subgroup differences 284
masking see blinding
matching 420–1
mean difference see difference in means;
standardized mean difference
measurement scales see scales
measures of agreement 155–6, 169
medians 176, 340
MEDLINE 98–102, 118
abstracts of Cochrane reviews 55
adverse effects 440–1
CENTRAL 119–21
citation versions 33–5
economics evidence 460
handsearching 107–8
identifiers 73
non-randomized studies 404, 406
patient-reported outcomes 536, 538
qualitative research 579
reporting bias 97, 305, 308
searching for reviews 111–12
searching for studies 125–31, 134–42
meta-analysis 6, 243–96, 481–529
benefits and limitations 246–7
baseline risk 288–9
Bayesian methods 210, 518–19
cross-over trials 502–7
data collection 162
data types
continuous outcome data 268–72, 290
counts 273–4, 521
dichotomous outcome data 265–8, 271–2,
520–3
generic inverse-variance outcome data 265
O – E and Variance data 266, 274–5, 555
ordinal outcome data 272–3
rate data 273–4
time-to-event data 274–5
dose-response analyses 289
economics evidence 470–1
effect measures 250–9, 279–80
difference in means 268–72
odds ratio 265–8, 271–2
risk difference 265–8
risk ratio 265–8
standardized mean difference 256–7,
268–9, 271–2
fixed-effect method 264, 279
forest plots 76, 337–40
heterogeneity 276–89
hierarchical models 519–20
indirect comparisons 513–15
individual patient data 520, 553–5
interpreting results 369–79
inverse-variance 264–5
Mantel-Haenszel methods 266, 282
meta-regression 284–9
methods sections 62
INDEX

missing data 482–93
multi-arm studies 508–12
multiple analyses 210, 226–30, 516–18, 541
multiple-treatments 510–11, 513–16, 621
non-randomized studies 413, 419–24
patient-reported outcomes 541–3
Peto method 266, 275, 521, 523
planning 244–6
precision 246, 264
pre-specification 249, 286, 288, 516–7
principles 263–4
prospective 564–5, 567–8
protocols 248–9
random-effects methods 263–5, 279–82
rare events 520–3
results sections 65–6, 351
RevMan 244, 248, 265, 272–6, 279, 281–4
risk of bias 188–90, 206–10, 247
scales 269, 272–3
sensitivity analyses 289–92, 319–21
skewed data 270–1
standard errors 244–6
statistical test 264, 338–9
subgroup analyses 282–8
vote counting 276
weights 263–4, 266, 269, 282, 320
meta-epidemiology 190, 208
meta-regression 284–9
baseline risk 288–9
figures 342
interpreting results 287–8
risk of bias 208
study characteristics 285–7
methods sections 58–63, 618–21
MID see minimally important difference
minimally important difference (MID) 371, 542
missing data 482–8
conditional outcomes 492–3
general principles 483–4
individual patient data 552, 556
intention to treat 488–93
methods sections 62
sensitivity analyses 290–1, 484, 491–2
standard deviations 485–8
types 482–3
see also imputations; incomplete outcome data; selective outcome reporting
mixed methods approach 573, 575
MTM see multiple-treatments meta-analysis
multi-arm studies 262, 508–13
factorial trials 508, 512–13
heterogeneity 511–12
meta-analysis 508–12
methods sections 62
risk of bias 509–10
multi-centre trials 561
multiple analyses 210, 226–30, 516–18, 541
body parts 262
intervention groups 62, 262, 508–13
publication 298, 304–5
reports 152, 168–9
treatment attempts 261–2
multiple-treatments meta-analysis (MTM) 510–11, 513–16, 621
narrative summaries 244–5, 468–70
narrow questions 91–3
National Library of Medicine (NLM) 100–1, 119–21, 123, 127
network meta-analysis see multiple-treatments meta-analysis
new citation versions 33–6, 37–9
Newcastle-Ottowa Scale 418, 424
next stage expected date 41, 54
NHS Economic Evaluation Database (NHS EED) 460–2, 463, 465, 470
NLM see National Library of Medicine
NNH see number needed to treat
NNT see number needed to treat
no longer updated date 41
Non-Randomized Studies Methods Group (NRS MG) 392–4, 396, 400, 403, 406–7, 418, 423, 428
non-randomized studies (NRS) 391–432
adjusted estimates 412, 416–7
adverse effects 397, 400, 427, 438, 443–5
aetiological research questions 399
benefits and limitations 392–5, 397
confounding 395, 397, 412, 416–17, 420–2
data collection 407–11
designs and design features 392–5, 398, 400–3
eligibility criteria 396–403, 407, 425
generic inverse-variance data 420
GRADE/quality of evidence 362, 366–7, 427
heterogeneity 412, 419, 423–4, 426
inclusion with randomized trials 394, 396–7, 405–8
interpreting results 424–8
meta-analysis 413, 419–24
precision 397–8
non-randomized studies (NRS) (Continued)
protocols 395–6, 414–15
public health and health promotion 594, 595
reporting bias 90, 404
resources and guidance 399–403, 406–7, 408–11, 414–18, 420–4, 427–8
risk of bias/quality 392, 394, 395, 397–9, 412–20, 425–6
searching 404–7
selecting studies 407–11
strength of evidence 426–7
NRS see non-randomized studies
NRS MG see Non-Randomized Studies
Methods Group
number needed to treat (NNT) 250, 254, 267–8, 373–7, 379
nursing-specific databases 103–4
O – E and Variance data 266, 274–5, 555
see also time-to-event data
objectives sections 57–8, 614, 618
observational studies see non-randomized studies
odds ratio (OR) 250–5
cluster-randomized trials 497
confidence intervals 369–70
data extraction 181–2
forest plots 338
funnel plots 314–6, 318
interpreting results 373–7
log scales 182, 259–60, 263, 312
meta-analysis 265–8, 271–2
non-randomized studies 421, 423
ordinal outcome data 257–8, 272–3
rare events 521–3
RevMan 339–40
standardized mean difference 271–2, 378–9
Summary of findings tables 346v7, 350
ongoing studies 72, 73, 113–18
ordinal outcome data 250, 257–8
data extraction 178
meta-analysis 272–3
sensitivity analyses 291
OR see odds ratio
other outcome data 75, 271, 275, 337, 340–1
outcomes
adverse effects 90, 433–48
change from baseline 172, 269–70
Characteristics of studies tables 337
Data and analysis section 74–5
data collection 157, 161–2
economics evidence 456–7
eligibility criteria 84, 87–90
GRADE/quality of evidence 360–1
primary 59, 89
reporting bias see selective outcome reporting
review questions 87–90
risk of bias summarization 205–6, 364
secondary 59, 89
Summary of findings tables 59, 88–9, 343–4, 348–9
see also continuous outcome data; count data; dichotomous outcome data; ordinal outcome data; other outcome data; rate data; time-to-event data
outcome reporting bias see selective outcome reporting
overview plots see forest top plots
Overviews of reviews 7, 607–31
abstracts 615–16
acknowledgements 624
analyses 615, 619–21
comparison with intervention reviews 614–5
conclusions 616, 623–4
data collection 614, 619
declarations of interest 624
definition 607
discussion sections 622–3
eligibility criteria 609–12, 614, 618–19, 625
design 620, 628–9
figures 630
format 613–30
GRADE/quality of evidence 620, 622, 623, 628–9
implications for intervention reviews 88, 93
methods sections 618–22
new material and analyses 612, 613, 620–1
objectives sections 618
organizational issues 608, 613
plain language summary 616
protocols 608, 624
quality of included reviews 613, 614, 620, 621
rationale 608, 609–12
references 625
results sections 621–2
searching 614, 619
tables 625–9
text sections 616–24
titles 613, 615
updates 613

P values 370–2
contour-enhanced funnel plot 313–5
data extraction 174–5, 181–2
funnel plot asymmetry test 315–6
meta-analysis test 264
multiple analyses 516–17
selection models 322
paired t-tests 501–2
pairwise comparisons 245, 248, 508–11
parallel group trials 498
partial economic evaluations 451
participants
background sections 58
Characteristics of studies tables 336
data collection 157–9
eligibility criteria 58, 85–6, 92
responsiveness 160
review questions 85–6, 92
patient preferences 369
Patient-Reported Outcomes Methods Group
(PRO MG) 531, 533, 543
patient-reported outcomes (PROs) 531–45
assessment and description 539
comparability 540–1
definitions 532–3, 534
importance 533–4
interpreting results 541–3
measurement of change 538
quality of life 533–6, 538, 540, 542–3
searching 538–9
validity of instruments 537–8
peer review 22, 303
performance bias 195
permission to publish 25–6
per-protocol analysis 221, 489
Peto method 266, 275, 521, 523
pharmaceutical industry trials registers
116–17
pharmacology-specific databases 103
PHHCP see public health and health promotion
Phillips checklist 465
PICO acronym 83, 84, 129
placebo-controlled trials 218
plain language summaries 55, 355–6, 616
plots see figures; forest plots; funnel plots
PMA MG see Prospective Meta-analysis
Methods Group
PMAs see prospective meta-analyses
pooled estimates see meta-analysis
population average effect 423
post hoc analyses 12, 286, 288, 351
PPP see Purchasing Power Parities
pre-specification
meta-analysis methods 249, 286, 288, 516–7
non-randomized studies 396, 415–6
outcomes 161
review methods 6, 84–5
selective outcome reporting 201
precision
confidence intervals 370
funnel plots 310
GRADE/quality of evidence 362, 365
meta-analysis 246, 264
non-randomized studies 397–8
risk of bias 189, 206, 233
searching 130, 136–9
preparation of Cochrane reviews 11–30
advisory groups 19–20
commercial sponsorship 26–8
consumer involvement 18–19
declarations of interest 26–8, 69, 624
editorial procedures 21–2, 46
format of Cochrane reviews 12–16
funding 24
logistics 13–24
motivation 13
permission to publish 25–6
protocols 11–12, 13, 17
publication in journals and books 24–6
resources 22–4, 427–8, 434, 436, 550, 562, 576
review teams 17–20
software 20–1, 52, 344–6
timeline 23, 24
topic and scope 13, 16–17
training 21
presentation of results see results sections;
Summary of findings tables
primary outcomes 59, 89, 201
PRO MG see Patient-Reported Outcomes
Methods Group
PROGRESS acronym 597–8
proportional odds model 257, 272–3
PROs see patient-reported outcomes
prospective meta-analyses (PMAs) 559–70
  collaborations 562–3
data collection 564, 566–7
definitions 559–61
eligibility criteria 559–61, 564–5
meta-analysis 564–5, 567–8
multi-centre trials 561
protocols 563–6
Prospective Meta-analysis Methods Group (PMA MG) 559, 562, 568
prospective trial registration 297
protocol information 52–5
protocols
  amendments 34–5
citation versions 33–4, 35–6
differences with reviews 69–70
economics evidence 453, 462
first published date 54
major change 34–36
meta-analysis 248–9
multiple analyses 481, 517
non-randomized studies 395–6, 414–15
outline 13–14
Overviews of reviews 624
prospective meta-analyses 563–6
rationale 11–12
registration 17
proximity operators 133–4
psychiatry-specific databases 104
psychology-specific databases 104, 107
PsycINFO 104, 107, 579
public health and health promotion (PHHP) 593–606
  applicability 601–3
  context 599–600
  ethics 597–8
inequalities 597–8
qualitative research 574–5
risk of bias/quality 595–7
searching 594–5, 596
study design 594
sustainability 600–1
transferability 601–3
publication bias 298–304
  causes 303–4
direct and indirect evidence 299–300
GRADE/quality of evidence 362, 365–6
multiple 298, 304–5
review questions 90
time lag bias 298, 300–3
trial registries 309–10
see also reporting bias
publication policies 24–6, 549, 564, 566
published notes 70
PubMed 100, 143–4
see also MEDLINE
Purchasing Power Parities (PPP) 468
QALY see quality-adjusted life years
QOL see quality of life
QRMG see Qualitative Research Methods Group
qualitative research 571–91
  critical appraisal/quality 580–1, 590–1
definitions 572–3
directly observed therapy 576–9
eligibility criteria 577
implementation of interventions 574–6, 578
integration with quantitative research 582–3, 589–90
mixed methods approach 573, 575
public health and health promotion 594–5, 596
randomized trials 575–6
resources 576, 587–91
review questions 574
searching 575, 577, 579–80, 589
strategies for addressing 573–6
synthesis 575, 576–83, 589–90
Qualitative Research Methods Group (QRMG) 572, 583–4
quality
  adverse effects 442–5
economics evidence 463–7, 470
evidence see GRADE
  interventions 160
  non-randomized studies 392, 394, 395, 397–9, 412–20, 425–6
  Overviews of reviews 613, 614, 620–3, 628–9
  public health and health promotion 595–7
  qualitative research 580–1, 590–1
  scales 190–2
  weights 191, 210
see also risk of bias
quality of life (QOL) 533–6, 538, 540, 542–3
quality-adjusted life years (QALY) 452, 457
quantitative synthesis see meta-analysis
quasi-randomized studies 122, 213, 392, 401, 409, 413
### INDEX

- **random-effects methods**: 263–5, 279–82
- **confidence intervals**: 370
- **dichotomous outcome data**: 266–7, 523
- **forest plots**: 338–9
- **multi-arm studies**: 511–12
- **reporting bias**: 319–21
- **RevMan**: 265, 267–9, 275, 282
- **sensitivity analyses**: 291, 319–21
- **tau-squared**: 281, 318, 338–9
- **randomization**: 193, 210–15, 552–3
- **randomized controlled trial (RCT)**: 119–23, 126, 136–9
- **randomized trials**
  - adverse effects: 434
  - GRADE/quality of evidence: 361–6
  - inclusion with non-randomized studies: 394, 396–7
- **public health and health promotion**: 594, 595
- **qualitative research**: 575–6
- **review questions**: 90–1
- **risk of bias**: 193–4, 210–34
- **searching**: 135–9
- **ranges**: 176
- **rare events**: 520–3
- **rate data**: 250, 258
  - data extraction: 178–9
  - meta-analysis: 273–4
- **ratio measures**: 182, 252–4, 350, 372–3
- **RCT**
  - see randomized controlled trial
- **RD**
  - see risk difference
- **references**: 72–4
  - managing: 142–4
  - Overviews of reviews: 625
  - searching: 110–11, 113
- **regional databases**: 101–2
- **regression models**: 420, 421–2
- **re-inclusions**: 221
- **related terms**: 131–2
- **relative effects**
  - see ratio measures
- **relative risk**
  - see risk ratio
- **relative risk reduction (RRR)**: 372–3
  - see also risk ratio
- **re-occurring events**: 261
- **repeated observations**: 261
- **reporting bias**: 297–333
  - avoidance: 308–10
  - citation bias: 298, 306
  - definitions: 298
  - detection: 310–23
  - economics evidence: 472–3
- **funnel plots**: 310–19
- **grey literature**: 308–9
- **heterogeneity**: 313, 318
- **individual patient data**: 556
- **language bias**: 298, 306–7
- **location bias**: 298, 305–6
- **methods sections**: 62, 249
- **non-randomized studies**: 90, 404
- **searching**: 97, 305–6, 308–10
- **selective outcome reporting**: 194, 226–30, 298, 307–9
- **sensitivity analyses**: 319–23
- **trial registries**: 309–10
- **unpublished studies**: 308–9
  - see also publication bias; risk of bias
- **reports**
  - see study reports
- **resources**
  - economics evidence: 450–1, 470–1
  - information sources: 98–128, 439–40, 450–2, 596
  - restricted randomization: 212–13
  - results sections: 63–66, 351–2, 621–2
  - retracted publications: 134–5
  - review information: 52–5
- **RevManager (RevMan) software**: 20–1
  - cluster-randomized trials: 495–7
  - cross-over trials: 502
  - data entry: 170–1, 175, 180–2
  - dates: 39, 54–5
  - figures: 76–7, 341–2
  - forest plots: 338–40
  - format of Cochrane reviews: 12–13, 52
- **headings**: 56
- **identifiers**: 166
- **indirect comparisons**: 514
- **individual patient data**: 555
- **meta-analysis**: 244, 248, 265, 272–6, 279, 281–4
- **non-randomized studies**: 420
- **funnel plots**: 312
- **P values**: 371–2
- **Risk of bias tool**: 202–4, 207–8
- **Summary of findings tables**: 344–6
- **review questions**: 83–94
  - broad versus narrow: 91–3
  - changing: 44, 93
  - eligibility criteria: 84–5, 91
  - interventions: 86–7, 92
review questions (Continued)
outcomes 87–90
participants 85–6, 92
studies 90–1
Summary of findings tables 343
review teams 17–20
RevMan see Review Manager
risk of bias 187–241
adverse effects 442–5
allocation concealment 193, 211, 214–17
assessment tools 190–3
see also Risk of bias tool
baseline imbalance 231–2
blinding 193–4, 217–9
cluster-randomized trials 494–5
continuous outcome data 200, 223–4, 227
cross-over trials 499–501
data collection 157–8, 192–3
data extraction 169
definitions 188–9
design-specific 230
dichotomous outcome data 200, 208, 223, 227
differential diagnostic activity 232
direction and magnitude 204–5
eyear stopping 231
economics evidence 463–7, 470
empirical evidence 190, 204, 211–12,
214–15, 217–18, 221, 226–7
figures/graphs 76–7, 202–4, 207
forest plots 207
funding 233
GRADE 362–4, 365–6
incomplete outcome data 194, 219–26
meta-analysis 188–90, 206–10, 247
methods sections 61
multi-arm studies 509–10
non-randomized studies 392, 394, 395,
397–9, 412–20, 425–6
other sources 233–4
Overviews of reviews 620, 623, 627
precision 189, 206, 233
presentation of assessments 202
public health and health promotion 595–7
quality 189–90
randomized trials 193–4, 210–34
rare events 523
reported 191
results sections 64–7
scales 190–2, 202
sensitivity analyses 209
sequence generation 193–8, 203, 210–14
summary assessments 202–6, 363–4
Summary of findings tables
tables 71, 202–3
time-to-event data 222
updates and amendments 42, 45
see also reporting bias
risk difference (RD) 250–1, 254–5
funnel plots 318–19
interpreting results 372–375
meta-analysis 265–8
rare events 522–523
Summary of findings tables 346–7
Risk of bias tool 194–202
allocation concealment 196, 198–9, 203–4
blinding 195–196, 199, 203–4, 217–19
descriptions 197
incomplete outcome data 195–196, 200,
203–4, 219–26
judgements 197–202
other sources 194, 233–4
RevMan 202–4, 207–8
selective outcome reporting 195–196, 201,
203–4, 228–30
sequence generation 196, 197–8, 203–4
unclear 197–202, 207, 213–14
risk ratio (RR) 250–5
funnel plots 318–19
interpreting results 372–4, 376–7
meta-analysis 265–8
rare events 521–3
Summary of findings tables 346–7
RR see risk ratio
RRR see relative risk reduction
scales 250, 257–8
data extraction 157, 161, 178
meta-analysis 269, 272–3
risk of bias/quality 190–2, 202
see also continuous outcome data; log scales;
ordinal outcome data
SCHARP software 555
SCI see Science Citation Index
Science Citation Index (SCI) 33, 35, 38, 55, 352
scope of review questions 91–3
searching 95–150
abstracts 98, 110, 143, 145, 406, 441–2
adverse effects 439–42
dates 40–1, 42, 54
documenting 59–60, 144–6
economics evidence 459–62
eligibility criteria 128
managing references 142–4
methods sections 59–60, 145–6
non-randomized studies 404–7
Overviews of reviews 614, 619
patient-reported outcomes 538–9
planning 118–28
public health and health promotion 594–5, 596
qualitative research 575, 577, 579–80, 589
references 110–11, 113
reporting bias 97, 305–6, 308–10
results sections 63, 145
sources 98–118
bibliographic databases 98–107
Cochrane Library 99–100, 119, 121, 124–6, 133–4
EMBASE 111–12, 125–31, 139
grey literature 106–7, 118, 145
journals 107–13
MEDLINE 111–12, 125–31, 134–42
ongoing/unpublished studies 113–18
strategies 128–42
Boolean operators 132–3, 141
eXamples 140–1
filters 135–9
proximity operators 133–4
restrictions 134
search filters 135–9
sensitivity and precision 130, 136–9, 141–2
service providers/search interfaces 129
structure 129
subject terms 130–2
updating 139–41
titles 98, 406, 441–2
Trials Search Co-ordinators 96–8, 102, 108, 118–19, 124–5, 143, 146
secondary outcomes 59, 89
selection bias 195, 211, 215
funnel plots 313
non-randomized studies 395, 412, 416
see also selective outcome reporting
selecting studies 152–6
selective outcome reporting 194, 226–30, 298, 307–9
results sections 65
Risk of bias tool 195–196, 201, 203–4, 228–30
sensitivity
analyses 289–92
cluster-randomized trials 498
cross-over trials 505–8
individual patient data 556
methods sections 63
missing data 484, 491–2
non-randomized studies 423
reporting bias 319–23
risk of bias 209
search strategy 130, 136–9, 141–2
sequence generation 193–8, 203, 210–14
results sections 65
Risk of bias tool 196, 197–8, 203–4
service providers 129
simple randomization 212
skewed data 176, 270–1
small study effects 312–13, 317, 319–24, 404
SMD see standardized mean difference
SMG see Statistical Methods Group
social healthcare-specific databases 104
social science-specific databases 104
socio-economic data 597–8
software 20–1, 52, 344–6
sources of support 26–7, 77
splitting reviews 44–5, 91, 93
standard deviations
cross-over trials 503, 506
data extraction 171, 173–7
missing 485–8
standardized mean differences 256, 269–270, 379
standard errors
cross-over trials 506–7
data extraction 171, 173–5, 181–2, 278–9
meta-analysis 264, 270, 274
standardized mean difference (SMD) 256–7, 377–9
change from baseline 270
cross-over trials 493
cross-over trials 504–5
funnel plots 318–19
interpreting results 377–9
meta-analysis 256–7, 268–9, 271–2
patient-reported outcomes 541, 542
statistical
heterogeneity see heterogeneity
significance 371–2
tests
funnel plot asymmetry 314–9
heterogeneity 277–8, 338–9
meta-analysis 264, 338–9
subgroup differences 284, 338–9
Statistical Methods Group (SMG) 292, 324
Steering Group 28
stratification 213, 420, 421
stratified randomization 213
structure see format of Cochrane reviews
studies awaiting classification 64, 71, 73
study reports
data collection 163
data extraction 167–70
eligibility criteria 97, 152
studies
Characteristics of studies tables 336
data collection 157–8
eligibility criteria 58, 90–1
review questions 58–60, 90–1
selecting 152–6
subgroup analyses 282–8
Data and analysis section 74–5
individual patient data 554–5
interpreting results 287–8
methods sections 62
study characteristics 285–7
test for differences 284, 338–9
subheadings 56
subject-specific databases 102–5
subject-specific trials registers 116, 124–5
summary assessments 202–6
Summary of findings tables 72, 342–50
detailed contents 348–50
GRADE/quality of evidence 342–4, 350, 360–7
outcome selection 88–9, 343–4
Overviews of reviews 620, 625–9
risk of bias 71, 202–3
Summary of findings 72, 342–350
tau-squared 281, 318, 338–9
tests see statistical tests
text sections 55–70, 616–24
authors’ conclusions sections 67
background sections 56–7
discussion sections 66–7
methods sections 58–63
objectives sections 57–8
Overviews of reviews 616–24
results sections 63–6, 351–2, 468–70
text words 130–1, 441–2, 539
thesaurus terms see controlled vocabulary
theses databases 106
time lag bias 298, 300–3
time-to-event data 250, 259
counts 179
data extraction 179–80
individual patient data 549, 554, 555
meta-analysis 274–5
risk of bias 222
sensitivity analyses 290
timeline for Cochrane reviews 23, 24
titles 52–3
adverse effects 441–2
non-randomized studies 406
Overviews of reviews 613, 615
results sections 348, 355–6
searching 98, 406, 441–2
selecting studies 153
TOCs see tables of contents
training 21
transferability 601–3
transformations 176
treatment effects 61, 244
trials registers 114–17, 124–5, 309–10
trials results registers 116–17
Trials Search Co-ordinators (TSC) 96–8, 102, 108, 118–19, 124–5, 143, 146
trim and fill method 321
TRIP see Turning Research into Practice
truncations 131–2
TSC see Trials Search Co-ordinators
INDEX

Turning Research into Practice (TRIP) 111
unclear risk of bias 197–202, 207, 213–14
unit-of-analysis errors 260–2, 493, 495, 502
unpublished studies 113–18, 308–9
unrestricted randomization 212
up-to-date reviews 40, 54
updates 33–4, 36, 37, 40–7
  methods sections 63
  Overviews of reviews 613
  searching 139, 141
validation of instruments 537–9
validity see risk of bias
variant spellings 131–2
vote counting 276

web searching 113
weighted mean difference (WMD) 256
weights
  meta-analysis 263–4, 266, 269,
  282, 320
  quality 191, 210
  well-being 532, 534
What’s new events 41, 46–7, 55
WHO see World Health Organization
wildcards 131–2
WinBUGS software 518–19
withdrawals see incomplete outcome data
WMD see weighted mean difference
World Health Organization (WHO) 114
zero frequencies 521–2

This index was prepared by Neil Manley, and edited by Julian Higgins.